Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Profit After Tax (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Profit After Tax readings, the most recent being $153.7 million for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 49.08% to $153.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $478.6 million, a 40.23% increase, with the full-year FY2025 number at $478.6 million, up 40.23% from a year prior.
  • Profit After Tax hit $153.7 million in Q4 2025 for Neurocrine Biosciences, down from $209.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $209.5 million in Q3 2025 to a low of -$76.6 million in Q1 2023.
  • Median Profit After Tax over the past 5 years was $66.8 million (2022), compared with a mean of $65.7 million.
  • Biggest five-year swings in Profit After Tax: surged 1319.18% in 2022 and later crashed 651.08% in 2023.
  • Neurocrine Biosciences' Profit After Tax stood at -$7.3 million in 2021, then surged by 1319.18% to $89.0 million in 2022, then soared by 65.96% to $147.7 million in 2023, then tumbled by 30.2% to $103.1 million in 2024, then skyrocketed by 49.08% to $153.7 million in 2025.
  • The last three reported values for Profit After Tax were $153.7 million (Q4 2025), $209.5 million (Q3 2025), and $107.5 million (Q2 2025) per Business Quant data.